Executive Vice President, Chief Financial Officer & Treasurer
As Karyopharm’s Chief Financial Officer, Mike is responsible for developing and implementing our financial and capital markets strategies, fundraising and advising on business development and transactional activities. On a day-to-day basis, Mike also leads our tax, treasury, accounting and financial planning and analysis activities. Mike joined the Company in September 2017.
Mike brings to Karyopharm over twenty-five years of experience in executing business growth and financial strategies for publicly-traded and privately-held companies, including senior financial leadership roles at healthcare-focused, scientific organizations. Prior to joining Karyopharm, he served as Chief Financial Officer at several high-growth, revenue-generating companies, including Seven Bridges Genomics, Analysis Group, Ahura Scientific and Aspect Medical Systems. Prior to that, Mr. Falvey served as Vice President, Finance at Millennium Pharmaceuticals, where he was responsible for leading all aspects of planning and executing financial strategy, including establishing financial functions around the launch of Velcade® (bortezomib) for the treatment of patients with multiple myeloma. Prior to Millennium, he also held financial positions at Fidelity Investments, Digital Equipment Corporation and General Electric.
Mike earned his Master of Science in Management from the Sloan School of Management at MIT, where he was also named a Seley Scholar. He earned his undergraduate degree from Georgetown University’s School of Foreign Service.
Chief Development Operations Officer